Combining our immunology and neuroscience expertise, we are continually developing our service offering and expanding to meet client demand.
We are developing a range of neurotoxicity services, including developmental neurotoxicity assays (DNT), using our pluripotent stem cell and primary CNS cell-based assay platforms that can support Pharma and non-Pharma clients in their regulatory and safety requirements.
We have a suite of cell-based approaches that include cytotoxicity, viability and proliferation assays, mitochondrial toxicity and calcium influx assays. We can tailor any program of work to suit your functional endpoints with custom readouts and bespoke experimental design.
Please get in touch to discuss our new neurotoxicity assays.